Summary:
This study is being done to see how the body processes the study drug tecovirimat, along with its’ safety and tolerability. The study will compare how this occurs in individuals with various levels of liver disease, as compared to individuals with normal liver function. The information gathered in this study will help to determine the proper dosing recommendations for the study drug.
Qualified Participants Must:
•
Be between 18 and 75 years of age
•
Have any degree of liver impairment
•
Smoke fewer than 10 cigarettes per day
•
Be willing to stay in our clinic for a period of 6 nights and 7 days
•
Not have any cancer or malignant liver tumor
Qualified Participants May Receive:
Compensation up to $1500 may be provided for time and travel.